OS Therapies Accepted Into Johnson & Johnson Innovation - JLABS

Rhea-AI Summary

OS Therapies (NYSE American: OSTX), a clinical-stage biopharmaceutical company, has been accepted into Johnson & Johnson Innovation – JLABS. The company aims to develop its tunable Antibody Drug Conjugate (ADC) linker-based platform at JLABS. This platform uses pH sensitive linkers & coating technology to reduce off-target effects, potentially improving safety and increasing the diversity of therapeutic payloads delivered.

OS Therapies' goal is to offer improved efficacy compared to other ADCs in the market or in development. The company's unique linker platform allows for the creation of new intellectual property for both novel and off-patent targeting antibodies and drug payloads. This development could potentially lead to more effective and safer ADC-based therapies in the future.

Positive

• Acceptance into Johnson & Johnson Innovation - JLABS, potentially providing valuable resources and networking opportunities
• Development of a tunable ADC linker-based platform with potential for improved safety and efficacy
• Opportunity to create new intellectual property for both novel and off-patent targeting antibodies and drug payloads

Negative

• None.

• Focus of work at JLABS on tunable Antibody Drug Conjugate linker-based platform

ROCKVILLE, Md.--(BUSINESS WIRE)-- OS Therapies (NYSE American: OSTX) (“OS Therapies” or “the Company”), an ADC and Immunotherapy research and clinical-stage biopharmaceutical company, today announced that it has been accepted into Johnson & Johnson Innovation – JLABS. Through membership of JLABS, OS Therapies aims to further develop and enter the clinic with its tunable Antibody Drug Conjugate (ADC) linker-based platform that relies on pH sensitive linkers & coating technology to reduce off-target effects to improve safety and increase the number & diversity of therapeutic payloads delivered. Through these developments, OS Therapies hopes to offer improved efficacy versus other ADCs in the market or in development. Drug candidates developed using OS Therapies’ tunable ADC platform leverage this unique linker platform to create new intellectual property for both novel and off-patent targeting antibodies and drug payloads.

About OS Therapies

OS Therapies is a clinical stage oncology company focused on the identification, development and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. OST-HER2, the Company’s lead asset, is an immunotherapy leveraging the immune-stimulatory effects of Listeria bacteria to initiate a strong immune response targeting the HER2 protein. The Company has completed enrollment for a 41-patient Phase 2b clinical trial of OST-HER2 in resected, recurrent osteosarcoma, with results expected in the fourth quarter of 2024. OST-HER2 has completed a Phase 1 clinical study primarily in breast cancer patients, in addition to showing strong preclinical efficacy data in various models of breast cancer. In addition, OS Therapies is advancing its next generation Antibody Drug Conjugate (ADC) platform, known as tunable ADC (tADC), which features tunable, tailored antibody-linker-payload candidates. This platform leverages the Company’s proprietary silicone linker technology, enabling the delivery of multiple payloads per linker. For more information, please visit www.ostherapies.com.

Forward-Looking Statements

Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute forward-looking statements within the meaning of the federal securities laws. These forward-looking statements and terms such as “anticipate,” “expect,” “intend,” “may,” “will,” “should” or other comparable terms involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Those statements include statements regarding the offer and sale of shares, the timing of the listing of OS Therapies’ common stock on the NYSE American, the timing of the closing of the offering, the use of the proceeds from the sale of shares of common stock in the offering, and the intent, belief or current expectations of OS Therapies and members of its management, as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, including those described under the caption “Risk Factors” and elsewhere in the prospectus filed with the SEC relating to the offering and that actual results may differ materially from those indicated by such forward-looking statements. Any forward-looking statements contained in this press release speak only as of the date hereof, and, except as required by the federal securities laws, OS Therapies specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240819756213/en/

Corporate and Media:

Jack Doll

410-297-7793

Irpr@ostherapies.com

Investor Relations:

Dave Gentry

RedChip Companies, Inc.

1-407-644-4256

OSTX@redchip.com

Source: OS Therapies

FAQ

What is the significance of OS Therapies (OSTX) being accepted into Johnson & Johnson Innovation - JLABS?

Being accepted into JLABS provides OS Therapies with access to valuable resources and networking opportunities to further develop their tunable Antibody Drug Conjugate (ADC) linker-based platform, potentially accelerating their research and development efforts.

What is the main focus of OS Therapies (OSTX) at JLABS?

OS Therapies will focus on developing their tunable Antibody Drug Conjugate (ADC) linker-based platform, which uses pH sensitive linkers and coating technology to reduce off-target effects and potentially improve safety and efficacy of ADC therapies.

How does OS Therapies (OSTX) aim to improve upon existing ADC therapies?

OS Therapies aims to offer improved efficacy compared to other ADCs by using their unique linker platform to reduce off-target effects, increase the diversity of therapeutic payloads delivered, and potentially create new intellectual property for both novel and off-patent targeting antibodies and drug payloads.